What will next-gen cancer cocktails cost? It's all about value, execs say
28 April 2016
Immuno-oncology drug developers have heard the debate about drug prices--and not only that. They’re listening. The first two cancer-fighting PD-1 drugs, Merck & Co’s Keytruda and Bristol-Myers Squibb’s Opdivo, both hit the market with six-figure prices. Others are soon to follow, including Roche’s atezolimumab, no doubt bearing similar price tags.
JAMA: Adding 3-D mammography decreases patient recalls, increases cancer detection
28 April 2016
Improving the accuracy of breast exams to detect cancer is at the forefront of research agendas since, in recent years, the necessity of routine screening--as well as vigorous surgical and radiation protocols--have been called into question.
Heated iron nanoparticles increase chemo effect
28 April 2016
A team of Japanese researchers from several institutions across the country announced they were able to enhance a nanoparticle drug delivery system by applying heat, giving the chemotherapy drug the added benefit of local hyperthermia in head and neck cancers.
Germany’s drug pricing amnesty reset risks pharma backlash
28 April 2016
Germany’s strict drug pricing controls may be about to get a whole lot harsher as the country’s government is mulling over whether to lift a lucrative pricing amnesty.
Aging R&D: The new, old thing in biotech
27 April 2016
If you ever wondered what kind of future to expect for R&D on drugs to slow the aging process, pay particularly close attention to this story from The Wall Street Journal.
Russians move inch closer to solving cardiac arrhythmia problem
27 April 2016
Russian biologists and physicists have developed technology enabling cardiac cell control with a laser. This is expected to pave the way for creating future solutions that may help rectify cardiac tissue excitability in arrhythmia cases, the Russian news agency RIA Novosti reported , citing a project-related article in PLoS One.
In Moscow, new laser to treat eye diseases
27 April 2016
Scientists at the Moscow Lomonosov State University (MSU) in partnership with colleagues from the Belarus National Technical University in neighboring Belarus have come up with what they claim is a unique laser to treat eye diseases, portal Hi-tech.mail.ru reported .
26 April 2016
Ñlearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.
Europe plans $7.5B region-wide cloud system to connect scientists
26 April 2016
European politicians are working to create a cloud platform on which the 1.7 million researchers and 70 million science and technology professionals in the region can store and share data. The plan is to eliminate digital barriers between scientists by establishing the European Union at the forefront of high-performance computing.
'Breakthrough' confusion prompts FDA to explain its terms
26 April 2016
What does "breakthrough" mean? The FDA set out to explain the designation last week after academic studies and the media reported widespread confusion about the term.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024